Laboratory Vacuum Pumps Market Size & Share 2026-2035

Laboratory Vacuum Pumps Market Size

The global laboratory vacuum pumps market was estimated at USD 1.9 billion in 2025. The market is expected to grow from USD 2 billion in 2026 to USD 3.5 billion in 2035, at a CAGR of 6.5% during the forecast period, according to the latest report published by Global Market Insights Inc..

Demand is anchored in workflows where pressure control affects sample integrity, process repeatability, or analytical sensitivity. Pharmaceutical laboratories use vacuum during filtration, solvent removal, drying, distillation, and freeze-drying, while hospitals and research laboratories require stable vacuum for mass spectrometry, chromatography, molecular diagnostics, microscopy, and sample preparation. The product decision increasingly turns on whether the process can tolerate oil exposure. Dry pumps avoid hydrocarbon contamination in sensitive pharmaceutical applications, whereas oil-sealed and liquid-ring systems remain relevant where deep vacuum, vapor handling, or initial equipment cost takes precedence.^{[1]Edwards Vacuum, edwardsvacuum.com}

North America accounts for USD 770.5 million, or 40.8% of market revenue, in 2025. Its lead reflects a concentrated base of pharmaceutical R&D, clinical testing infrastructure, and grant-funded biomedical laboratories. NIH research awards exceeded USD 36 billion in FY2025, sustaining equipment demand across academic medical centers, research institutes, and affiliated life-sciences ventures. Asia Pacific is forecast to record the highest regional CAGR, at 7.7%, as pharmaceutical manufacturing, CDMO capacity, and laboratory networks expand in China and India.^{[2]Nash Pumps, nashpumps.com} India's CRDMO market is projected to grow at a 14.0% CAGR between 2023 and 2028, creating demand for quality-control, process-development, and analytical laboratory equipment alongside production capacity.

The expansion of biopharma investment reinforces this transition. Global biopharma funding reached USD 102 billion in 2024, supporting a wider base of companies conducting discovery, scale-up, and manufacturing-support work that requires contamination-controlled laboratory infrastructure. Oil-sealed pumps will retain a role in deep-vacuum and vapor-intensive duties, but suppliers able to demonstrate clean operation and application-specific performance should capture a larger share of new regulated installations. This supports the projected 6.8% CAGR for dry pumps, compared with 6.1% for wet systems, through 2035.

Key Drivers

Increasing Demand for Diagnostic Laboratories in the Healthcare Sector

Diagnostic capacity increases the installed base of vacuum-dependent analytical equipment rather than producing a one-time equipment event. Quest Diagnostics reported approximately 7% revenue growth for full-year 2024 and nearly 15% growth in the fourth quarter, while its August 2024 acquisition of LifeLabs expanded its laboratory network into Canada. As molecular assays, liquid chromatography, and mass spectrometry move into regional hospitals and distributed diagnostic facilities, vacuum requirements extend beyond a small number of centralized reference laboratories.

This decentralization favors compact, low-noise, readily serviceable pumps. The addressable opportunity is particularly significant where laboratory groups standardize platforms across a network, because equipment suppliers can compete for repeat purchases, preventive maintenance, and replacement demand. IDH processed more than 39.2 million diagnostic tests for over 8.9 million patients in 2024 across its operating markets, illustrating the scale at which expanding laboratory operators can drive recurring demand for analytical infrastructure. ^{[3]The Scientist, the-scientist.com}

Growth in Pharmaceutical and Biotechnology Research Activities

Pharmaceutical R&D creates demand throughout the laboratory lifecycle, from medicinal chemistry and formulation work to analytical quality control and process development. IQVIA reported that leading pharmaceutical companies' R&D expenditure exceeded USD 190 billion in 2024, while aggregate biopharma funding reached a 10-year high of USD 102 billion. These investments support laboratories with different vacuum specifications: compact diaphragm systems for bench work, rotary vane pumps for deep-vacuum applications, and dry screw or claw pumps for larger, contamination-sensitive processes.

Biologics, cell and gene therapies, and vaccine programs intensify the requirement for controlled drying and solvent-removal steps. Freeze-drying applications require reliable vacuum conditions to protect temperature-sensitive products, making vacuum performance, vapor handling, and maintenance planning material to process continuity. Suppliers that can match pump construction and controls to these specific workflows are better positioned than suppliers competing on flow rate alone.

Rising Adoption of Advanced Medical Devices Requiring Vacuum Technology

Higher-sensitivity instruments expand the technical demands placed on laboratory vacuum systems. Mass spectrometers, electron microscopes, and chromatography platforms depend on stable backing vacuum to maintain measurement performance and instrument uptime. In contamination-sensitive applications, oil-free air and vacuum quality become part of the instrument manufacturer's quality assurance proposition. Atlas Copco's DZS and DHS oil-free pumps have received TÜV Rheinland verification under ISO 8573-1 Class 0, supporting use cases where oil contamination cannot be tolerated.

The commercial implication is that medical-device and analytical-instrument growth does not benefit all pump designs equally. Suppliers must provide performance documentation, low vibration and noise characteristics, and service support compatible with high-value instruments that cannot be routinely taken offline. ^{[4]Sai Life Sciences, sailife.com}

Expanding Biopharmaceutical Industry and Vaccine Production

Biopharmaceutical capacity projects produce demand in both manufacturing and adjacent laboratory environments. Sanofi announced an approximately EUR 1 billion investment in an insulin production facility in Beijing in December 2024. WuXi AppTec also broke ground on a Singapore site in Tuas Biomedical Park intended to expand its global manufacturing support capacity. In India, Aurigene Pharmaceutical Services opened a biologics facility in Hyderabad, and Amneal Pharmaceuticals announced plans to invest up to USD 200 million in two new manufacturing plants.

Each facility requires quality-control, stability-testing, and process-development laboratories. Vacuum systems are therefore purchased not only for production-scale drying or recovery operations, but also for analytical laboratories that validate materials and monitor batches. ^{[5]IQVIA Institute, makingpharmaindustry.it} This creates a broader revenue pool for laboratory-focused suppliers as biopharma capital expenditure moves into new manufacturing geographies.

Technological Advancements

Technology upgrades are making replacement purchases more commercially attractive. LADS, an OPC UA companion specification for laboratory and analytical devices, enables standardized communication between compatible vacuum controllers and laboratory software systems. This capability can improve traceability where laboratories need recorded process conditions or centralized equipment oversight.

Equipment design is also addressing energy and usability constraints. Leybold's DRYVAC systems incorporate the VAControl platform for monitoring and connected pump management. KNF's LABOPORT diaphragm pumps use speed-controlled motors and integrated vacuum controls for applications such as evaporation, filtration, and degassing. These features shift procurement discussions toward lifecycle cost, process repeatability, and labor efficiency, especially in high-throughput laboratories.

Key Restraints

Stringent Regulatory Requirements for Medical Devices and Lab Equipment

Regulated laboratories must evaluate vacuum equipment within wider quality-management and validation systems. FDA device regulation requirements govern manufacturing and quality processes for medical devices, while laboratories operating under GMP need documented equipment qualification, change control, and maintenance records for equipment affecting controlled processes. These obligations can delay adoption when a replacement pump requires requalification, updated operating procedures, or validation evidence.

The restraint is most pronounced in pharmaceutical manufacturing and clinical diagnostics, where the purchase decision includes documentation and implementation risk. For suppliers, compliance support can mitigate the barrier. Application documentation, validated operating configurations, and controller-generated audit trails can reduce the burden placed on laboratory engineering and quality teams.

Maintenance Challenges and Operational Costs of Certain Vacuum Pumps

Oil-sealed rotary vane vacuum pumps remain technically valuable, particularly in applications requiring deep vacuum or high pumping speed, but their lifecycle economics can be less favorable in solvent- and moisture-intensive work. Oil changes, exhaust filtration, cold traps, and disposal requirements add operating cost and create downtime exposure. These costs are amplified in laboratories that run continuous analytical or quality-control schedules.

Dry systems avoid many oil-related maintenance requirements, but their higher purchase cost and periodic diaphragm or valve replacements can remain obstacles for smaller institutions. Lifecycle-cost assessments are often less developed in price-sensitive markets, which can sustain demand for lower-cost legacy designs despite higher operating burdens. This slows replacement conversion, particularly where service access and consumable availability are inconsistent.^{[6]Process Worldwide, process-worldwide.com}

Maintenance economics create a parallel divide. Leybold states that its SOGEVAC SV55/70 BI² pumps can operate for up to 24,000 hours without maintenance in LC/GC-MS applications, while Ebara positions its EV-SA dry pump series for operation with minimal maintenance over extended periods. Such claims matter because unplanned downtime can interrupt analytical throughput and qualification schedules. Suppliers with both durable legacy offerings and credible dry-pump alternatives can address laboratories at different points in their replacement cycle, rather than forcing a single technology transition.

Laboratory Vacuum Pumps Market Segment Analysis

By Product

Dry Vacuum Pumps held 59.7% of market revenue in 2025 and are projected to reach USD 2,200 million by 2035, expanding at a CAGR of 6.8%. Their growth is tied to pharmaceutical and biotechnology applications where oil carryover or backstreaming can threaten sample quality, product integrity, and validation requirements. Dry diaphragm, screw, and claw designs serve different pressure and flow requirements, enabling suppliers to address bench-scale filtration as well as pilot and production-support work.^{[7]VACUUBRAND, vacuubrand.com}

VACUUBRAND's VACUU·PURE 10 demonstrates the technical extension of dry technology into deeper-vacuum applications, offering oil-free vacuum down to 10⁻³ mbar. The category's advantage is strongest where laboratories weigh contamination control and maintenance reduction more heavily than initial purchase cost.

Wet Vacuum Pumps are projected to reach USD 1,200 million by 2035, at a CAGR of 6.1%. Oil-sealed rotary vane pumps retain importance for deep-vacuum duties, including analytical instrument backing, freeze-drying, and synthetic chemistry. Liquid-ring systems remain useful for wet and solvent-laden processes because the operating liquid can support vapor handling. DEKKER's ChemSeal systems are designed for pharmaceutical and chemical solvent-recovery applications, illustrating the continued relevance of liquid-ring equipment in process-oriented laboratories.

Improved rotary vane products can preserve this segment's role by reducing historical drawbacks. Leybold's SOGEVAC SV55/70 BI² series is positioned for LC-MS and GC-MS applications, with reported reductions in average power consumption of up to 38%, weight reductions of up to 46%, and maintenance-free operation of up to 24,000 hours.

Combination Vacuum Pumps are projected to reach USD 178.6 million by 2035, growing at a CAGR of 5.8%. Hybrid arrangements are selected where one pump architecture cannot meet both contamination-control and deep-vacuum requirements. Their narrower application base limits growth, but they remain relevant in specialized distillation, synthesis, and high-vacuum analytical workflows.^{[8]Quest Diagnostics, newsroom.questdiagnostics.com}

By Technology

Rotary Vane technology is projected to reach USD 1,600 million by 2035, advancing at a CAGR of 7.0%. The segment benefits from an extensive installed base and continued relevance in high-performance analytical applications. New designs are improving energy use, noise, monitoring, and vapor compatibility. Pfeiffer Vacuum+Fab Solutions introduced its DuoVane series with pumping speeds from 6 to 22 m³/h, improved water-vapor compatibility, and IE2-class motors for laboratory and process applications.

Rotary Screw pumps are projected to reach USD 1,100 million by 2035, at a CAGR of 6.4%. Their non-contacting rotor configuration and oil-free process chamber are well suited to pharmaceutical drying, distillation, and vapor-heavy processes. Busch's COBRA DH dry screw pump incorporates variable-speed control, a touchscreen interface, and Ethernet connectivity, with the product positioned for digitally connected industrial environments.^{[9]Quest Diagnostics, ir.questdiagnostics.com}

Rotary Claw technology is forecast to reach USD 649.2 million by 2035, growing at a CAGR of 6.1%. Claw pumps offer oil-free operation and reduced internal contact, attributes that are valuable in chemical and pharmaceutical service where particulate generation and process contamination must be minimized. Edwards' EDP 80–400 series applies reverse-claw technology to chemical and pharmaceutical applications requiring ultimate pressures below 1 mbar.

Other Technologies, including diaphragm, scroll, and piston pumps, are projected to reach USD 258.3 million by 2035, at a CAGR of 5.9%. Diaphragm pumps remain central to routine filtration, evaporation, and degassing because they combine compact form factors with oil-free operation. KNF's N 952 pump reaches an ultimate vacuum of 1.5 mbar with a flow rate of up to 36 L/min, supporting laboratory and instrument-backing applications.

By Application

Filtering is projected to be the fastest-growing application, expanding at a CAGR of 7.0% and reaching USD 1,300 million by 2035. Vacuum filtration is embedded in sample preparation, sterility testing, media preparation, molecular biology, and pharmaceutical quality control. Growth in molecular diagnostics and bioanalytical testing supports recurring demand because these workflows consume vacuum capacity across large numbers of samples rather than only during capital-project commissioning.

Drying is projected to reach USD 1,000 million by 2035, at a CAGR of 6.3%. Freeze-drying, vacuum ovens, and rotary evaporation require stable pressure control during solvent removal and preservation of sensitive materials. Biologics and vaccines increase the importance of these applications because formulation integrity depends on consistent process conditions.

Distillation is projected to reach USD 949.3 million by 2035, growing at a CAGR of 6.8%. Pharmaceutical process chemistry uses vacuum distillation and evaporation to concentrate, purify, and recover materials. Electronically controlled pumps and vacuum controllers can improve repeatability when temperature-sensitive compounds require tightly managed evaporation conditions.

Other Applications are projected to reach USD 234.1 million by 2035, at a CAGR of 4.8%. This category includes gas sampling, degassing, impregnation, pick-and-place operations, and backing systems for analytical instruments. Its slower growth reflects fragmented purchasing patterns and narrower application-specific requirements.

By End Use

Pharmaceutical and Biotechnology Companies generated USD 927.1 million in revenue in 2025, making them the largest end-use segment. Their demand combines greenfield installation requirements with replacement demand from established facilities. The shift toward dry, oil-free systems is most pronounced in GMP-sensitive processes, where the cost of contamination or incomplete documentation can exceed the equipment purchase price. ^{[10]IDH, investors.idhcorp.com}

Hospitals and Diagnostic Labs are projected to reach USD 1,100 million by 2035, advancing at a CAGR of 6.4%. Demand reflects the movement of molecular diagnostics, mass spectrometry, and high-sensitivity immunoassays into hospital and regional laboratory settings. Space limits, noise sensitivity, and the need for reliable daily operation favor compact and low-maintenance equipment.

Academic and Research Institutes are projected to reach USD 366.6 million by 2035, at a CAGR of 5.9%. Public research funding supports an installed base of university and medical-center laboratories, but purchasing is often constrained by grant timing and institutional procurement cycles. NIH funding remains an important demand anchor in the United States.

Other End Users, including food and beverage laboratories, environmental testing providers, industrial R&D sites, and electronics-related laboratories, are projected to reach USD 262.7 million by 2035, growing at a CAGR of 5.7%.

The strongest commercial position therefore sits with suppliers that can span bench-scale diaphragm products, high-throughput dry systems, and analytical-grade rotary vane equipment. Connectivity increases the value of this breadth when it links equipment status to laboratory control systems. VACUUBRAND's LADS-enabled controller approach and Leybold's VAControl platform show how vacuum suppliers are extending their offer from hardware performance into operational visibility. This is especially relevant in hospitals and pharmaceutical laboratories, where equipment availability and traceability can influence workflow scheduling as much as pump specifications.

Laboratory Vacuum Pumps Market Regional Analysis

North America

North America generated USD 770.5 million in 2025 and is projected to reach USD 1,379.0 million by 2035, at a CAGR of 6.0%. The U.S. accounted for USD 735.2 million in 2025. Its market scale stems from the concentration of pharmaceutical R&D, biomanufacturing, clinical reference laboratories, and publicly funded biomedical research. NIH awards exceeding USD 36 billion in FY2025 provide a sustained funding base for research-intensive institutions.

The region's mature regulatory environment raises barriers to supplier switching, particularly in clinical and pharmaceutical applications. FDA requirements increase the value of established suppliers that can provide reliable technical documentation, application support, and responsive service. Quest Diagnostics' acquisition of LifeLabs also illustrates how laboratory-network consolidation can expand procurement across North American diagnostic operations.

Europe

Europe is estimated at USD 539.7 million in 2025 and is projected to reach USD 987.5 million by 2035, growing at a CAGR of 6.3%. Germany remains central to regional demand because it combines a major pharmaceutical and chemical base with a dense cluster of vacuum-equipment manufacturers. The United Kingdom and France contribute through large biopharmaceutical research and manufacturing ecosystems.

European demand is supported by laboratory modernization and the high value placed on quality assurance, environmental performance, and equipment traceability. These conditions favor energy-efficient dry systems and connected controllers, but formal qualification requirements can lengthen replacement cycles. The region remains attractive for suppliers able to support both technically demanding process applications and decentralized academic laboratories.

Asia Pacific

Asia Pacific is forecast to grow from USD 373.4 million in 2025 to USD 782.1 million by 2035, at a CAGR of 7.7%. China and India account for much of this momentum as life-sciences manufacturing and laboratory infrastructure expand. CBRE identified Beijing and Shanghai among globally significant life-sciences markets with substantial R&D space under construction, reflecting the scale of China's laboratory expansion. Sanofi's Beijing insulin-facility investment further signals multinational commitment to Chinese biopharmaceutical capacity.

India's opportunity is shaped by CDMO and CRDMO expansion. The projected 14.0% CAGR for India's CRDMO sector between 2023 and 2028 indicates growing requirements for development, testing, and manufacturing-support laboratories. New investments by Aurigene and Amneal reinforce this direction. Japan, South Korea, and Australia add higher-value demand through advanced analytical, life-sciences, and research settings. ULVAC reported consolidated sales of ¥261.1 billion for the fiscal year ended June 2024, demonstrating the scale of Asia-headquartered vacuum technology suppliers serving regional industrial and analytical markets.

Latin America

Latin America is estimated at USD 129.6 million in 2025 and is projected to reach USD 253.2 million by 2035, expanding at a CAGR of 7.0%. Brazil is the region's largest source of pharmaceutical manufacturing and public-health laboratory demand, while Mexico benefits from investment in export-oriented manufacturing and associated quality-control capability.

Growth is moderated by import dependence, currency volatility, and uneven access to specialized maintenance services. These conditions make reliability, local support, and lifecycle-cost transparency particularly important. Suppliers that can support distributors with applications expertise and service parts may have an advantage over companies selling equipment without a local maintenance model.

Middle East and Africa

The Middle East and Africa market is estimated at USD 74.1 million in 2025 and is projected to reach USD 140.4 million by 2035, at a CAGR of 6.6%. Demand is linked to hospital laboratory modernization, diagnostic network expansion, and investment in domestic pharmaceutical capacity. Saudi Arabia and the UAE are important regional procurement centers, while South Africa provides a larger established base of clinical laboratories and pharmaceutical manufacturing.

The region's laboratory demand remains diverse, ranging from advanced hospital diagnostics to developing private reference networks. IDH's operations across Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan processed more than 39.2 million tests in 2024, illustrating the expanding scale of diagnostic activity across several Middle East and African markets. Standardized equipment, durable designs, and accessible service support are likely to carry greater commercial weight than highly customized digital functionality in many installations.

Regional commercialization models will need to diverge. North America and Europe reward documented compliance, application engineering, and connected equipment that can fit validated operations. In Latin America and parts of the Middle East and Africa, uptime, service coverage, and ownership cost may be more decisive because precision equipment is often imported and maintenance access is less consistent. The suppliers best placed to capture growth will combine technology differentiation with regional service capability rather than treating geographic expansion as a distribution-only exercise.

Laboratory Vacuum Pumps Market Share & Competitive Landscape

The market is moderately consolidated. Atlas Copco, BUSCH, KNF, VACUUBRAND, and Agilent collectively account for approximately 45% of global revenue. Competition is shaped by application specialization, oil-free technology, vacuum depth, vapor tolerance, connected controls, qualification support, and service reach.

Recent Industry Developments

• July 2024 - EDWARDS (Atlas Copco): Edwards Vacuum announced the commercial launch of the oil-free EDP 80–400 vacuum pump series targeting pharmaceutical and chemical applications.
• November 2024 - ULVAC, Inc.: ULVAC launched the Gv135 oil rotary vacuum pump for analytical and laboratory equipment requiring stable, low-noise operation.
• June 2025 - Leybold (Atlas Copco): Leybold introduced the SOGEVAC SV55 BI² and SV70 BI² specifically optimized for LC-MS and GC-MS instrumentatio.
• 2026 - VACUUBRAND: VACUUBRAND showcased vacuum pumps with an integrated LADS OPC UA interface at Analytica Munich 2026.